A new Research Triangle company, Persistence Therapeutics, is developing a small, implantable device that generates and delivers genetically engineered T cells directly inside the body. These cells, ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

SOUTH SAN FRANCISCO, Calif. & MADISON, Wis., February 18, 2026--Cellares, the first Integrated Development and Manufacturing ...

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy. In this interview, Michael Wang, MD, comments on ...

A method called "in vivo CAR-T (in vivo CAR-T·intra-body CAR-T)" that directly alters immune cells within the body with a single injection is recently changing the landscape of the cancer treatment ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...